according to the Globally Harmonized System



# Molnupiravir Capsule Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.07.2024
8.0		6199210-00014	Date of first issue: 24.08.2020

## **1. PRODUCT AND COMPANY IDENTIFICATION**

Product name	:	Molnupiravir Capsule Formulation						
Manufacturer or supplier's details								
Company	:	MSD						
Address	:	Briahnager - Off Pune Nagar Road Wagholi - Pune - India 412 207						
Telephone	:	+1-908-740-4000						
Emergency telephone number	:	+1-908-423-6000						
E-mail address	:	EHSDATASTEWARD@msd.com						
Recommended use of the chemical and restrictions on use								
Recommended use Restrictions on use	:	Pharmaceutical Not applicable						

## 2. HAZARDS IDENTIFICATION

#### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

#### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification Skin corrosion/irritation	:	Category 3
Specific target organ toxicity - repeated exposure (Oral)	:	Category 1 (Gastrointestinal tract)
GHS label elements		
Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H316 Causes mild skin irritation. H372 Causes damage to organs (Gastrointestinal tract) through prolonged or repeated exposure if swallowed.
Precautionary statements	:	<b>Prevention:</b> P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.

according to the Globally Harmonized System



# Molnupiravir Capsule Formulation

Version 8.0	Revision Date: 28.09.2024	SDS Number: 6199210-00014	Date of last issue: 06.07.2024 Date of first issue: 24.08.2020		
			nds thoroughly after handling. at, drink or smoke when using this product.		
		Response:			
			P319 Get medical help if you feel unwell. P332 + P317 If skin irritation occurs: Get medical help.		
		Disposal:			
		P501 Dispose disposal plant.	of contents/ container to an approved waste		

#### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. May form explosive dust-air mixture during processing, handling or other means.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	: Mixture		
Components			
Chemical name		CAS-No.	Concentration (% w/w)
Cellulose		9004-34-6	>= 70 - < 90
Molnupiravir		2492423-29-5	>= 70 - < 90

#### 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes mild skin irritation. Causes damage to organs through prolonged or repeated exposure if swallowed. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

**5. FIREFIGHTING MEASURES** 

according to the Globally Harmonized System




# Molnupiravir Capsule Formulation

Vers 8.0	sion	Revision Date: 28.09.2024		99210-00014	Date of last issue: 06.07.2024 Date of first issue: 24.08.2020
	Suitable extinguishing media		:	Water spray Alcohol-resistant f Carbon dioxide (C Dry chemical	
	Unsuitable extinguishing media		:	None known.	
	Specific hazards during fire- fighting		:	Exposure to comb	oustion products may be a hazard to health.
	Hazardous combustion prod- ucts		:	Carbon oxides Metal oxides	
	Specific extinguishing meth- ods		:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to so. Evacuate area.	
	Special for firef	protective equipment ghters	:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	<ul> <li>Sweep up or vacuum up spillage and collect in suitable container for disposal.</li> <li>Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).</li> <li>Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.</li> <li>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.</li> <li>Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</li> </ul>

## 7. HANDLING AND STORAGE





# Molnupiravir Capsule Formulation

Versio 8.0	on	Revision Date: 28.09.2024		DS Number: 99210-00014	Date of last issue: 06.07.2024 Date of first issue: 24.08.2020		
Technical measures		:	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding				
	Local/Total ventilation Advice on safe handling		:::	<ul> <li>and bonding, or inert atmospheres.</li> <li>Use only with adequate ventilation.</li> <li>Do not get on skin or clothing.</li> <li>Do not breathe dust, fume, gas, mist, vapours or spray.</li> <li>Do not swallow.</li> <li>Avoid contact with eyes.</li> <li>Wash skin thoroughly after handling.</li> <li>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment</li> <li>Minimize dust generation and accumulation.</li> <li>Keep away from heat and sources of ignition.</li> <li>Take precautionary measures against static discharges.</li> <li>Do not eat, drink or smoke when using this product.</li> <li>Take care to prevent spills, waste and minimize release to the</li> </ul>			
		ons for safe storage als to avoid	:	Store in accordan	abelled containers. ce with the particular national regulations. the following product types: agents		

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Cellulose	9004-34-6	TWA	10 mg/m3	ACGIH
Molnupiravir	2492423-29- 5	TWA	20 µg/m3 (OEB 3)	Internal
		Wipe limit	200 µg/100cm2	Internal

Engineering measures
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.
 Personal protective equipment

Respiratory protection :		If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection.	
Filter type	:	Particulates type	
Hand protection			

according to the Globally Harmonized System



# Molnupiravir Capsule Formulation

Version 8.0	Revision Date: 28.09.2024	SDS Number: 6199210-00014	Date of last issue: 06.07.2024 Date of first issue: 24.08.2020		
M	aterial	: Chemical-res	istant gloves		
Remarks Eye protection		: Wear safety of If the work en mists or aeros Wear a faces	Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.		
Skin and body protection		Additional boo being perform suits) to avoid Use appropria	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.		
Hygiene measures		: If exposure to flushing syste place. When using o Wash contam The effective engineering o appropriate d industrial hyg	o chemical is likely during typical use, provide eye oms and safety showers close to the working to not eat, drink or smoke. inated clothing before re-use. operation of a facility should include review of ontrols, proper personal protective equipment, egowning and decontamination procedures, iene monitoring, medical surveillance and the strative controls.		

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	solid
Colour	:	white to off-white
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available

according to the Globally Harmonized System



# Molnupiravir Capsule Formulation

Vers 8.0	sion	Revision Date: 28.09.2024		S Number: 99210-00014	Date of last issue: 06.07.2024 Date of first issue: 24.08.2020
		explosion limit / Lower bility limit	:	No data available	
	Vapour	pressure	:	Not applicable	
	Relative	e vapour density	:	Not applicable	
	Relative	e density	:	No data available	)
	Density	,	:	No data available	)
	Solubili Wat	ty(ies) er solubility	:	No data available	9
	Partition octanol	n coefficient: n- /water	:	Not applicable	
		nition temperature	:	No data available	3
	Decom	position temperature	:	No data available	)
	Viscosi Visc	ty osity, kinematic	:	Not applicable	
	Explosi	ve properties	:	Not explosive	
	Oxidizir	ng properties	:	The substance of	r mixture is not classified as oxidizing.
	Molecu	lar weight	:	No data available	
	Particle Particle	characteristics size	:	No data available	)

## **10. STABILITY AND REACTIVITY**

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

## 11. TOXICOLOGICAL INFORMATION

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

according to the Globally Harmonized System



# **Molnupiravir Capsule Formulation**

Version 8.0	Revision Date: 28.09.2024		DS Number: 99210-00014	Date of last issue: 06.07.2024 Date of first issue: 24.08.2020
Not cl	<b>e toxicity</b> assified based on avail ponents:	lable	information.	
Cellu	lose:			
Acute	oral toxicity	:	LD50 (Rat): > 5,0	00 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 5.8 Exposure time: 4 Test atmosphere	h
Acute	dermal toxicity	:	LD50 (Rabbit): >	2,000 mg/kg
Molnu	upiravir:			
Acute	oral toxicity	:	LD0 (Rat): 2,000	mg/kg
			LD0 (Dog): 2,000	mg/kg
	corrosion/irritation es mild skin irritation.			
<u>Comp</u>	oonents:			
Molnu	upiravir:			
Speci		:		man epidermis (RhE)
Metho Resul		:	EpiDerm Mild skin irritation	I
Not cl	us eye damage/eye ir assified based on avai ponents:			

### Molnupiravir:

Species	:	Bovine cornea
Method	:	Bovine cornea (BCOP)
Result	:	No eye irritation

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Germ cell mutagenicity

Not classified based on available information.

#### Components:

Cellulose:

according to the Globally Harmonized System



# **Molnupiravir Capsule Formulation**

sion	Revision Date: 28.09.2024	SDS Nur 6199210		Date of last issue: 06.07.2024 Date of first issue: 24.08.2020
Geno	toxicity in vitro	Resu	It: negative	
			l ype: In vi lt: negative	tro mammalian cell gene mutation test
Geno	toxicity in vivo	cytog Spec Appli	enetic ass ies: Mouse	e ite: Ingestion
Moln	upiravir:			
Geno	toxicity in vitro		Type: Ame It: positive	es test
		Test		onucleus test Iman lymphoblastoid cells e
Genotoxicity in vivo	Spec Cell t Appli	Type: Micr ies: Rat ype: Bone cation Rou It: negative	ite: Oral	
		cytog Spec Cell t		
		cytog Spec Appli		te: Oral
	cell mutagenicity -		ht of evide nutagen.	nce does not support classification as a ge

#### Components:

## Cellulose:

Species	: F	Rat
Application Route	: 1	ngestion
Exposure time	: 7	2 weeks
Result	: n	egative

according to the Globally Harmonized System



# Molnupiravir Capsule Formulation

Version 8.0	Revision Date: 28.09.2024		DS Number: 99210-00014	Date of last issue: 06.07.2024 Date of first issue: 24.08.2020
Not c	oductive toxicity lassified based on avai ponents:	lable	information.	
Cellu		:	Test Type: One- Species: Rat Application Rout Result: negative	generation reproduction toxicity study e: Ingestion
Effec ment	ts on foetal develop-	:	Test Type: Fertili Species: Rat Application Rout Result: negative	ity/early embryonic development e: Ingestion
	<b>upiravir:</b> ts on foetal develop-	:	Species: Rat Application Rout Developmental T Symptoms: Effect ment Result: No effect ment were detect Remarks: Not cla	oxicity: LOAEL: > 200 mg/kg body weight ots on embryofoetal and postnatal develop- s on fertility and early embryonic develop-

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Causes damage to organs (Gastrointestinal tract) through prolonged or repeated exposure if swallowed.

# Components:

#### Molnupiravir:

Exposure routes	: Oral	
Target Organs	: Gastroin	testinal tract
Exposure routes Target Organs Assessment	: Causes exposure	damage to organs through prolonged or repeated
11	CAPOSUL	J.

#### Repeated dose toxicity

#### **Components:**

#### Cellulose:

Species NOAEL Application Route Exposure time	: Rat
NOAEL	: >= 9,000 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

according to the Globally Harmonized System



# Molnupiravir Capsule Formulation

Version 8.0	Revision Date: 28.09.2024	SDS Number: 6199210-00014	Date of last issue: 06.07.2024 Date of first issue: 24.08.2020
Speci LOAE Expos		: Rat : 2,000 mg/kg : 7 d : Stomach	
	EL sure time et Organs	: Dog : 300 mg/kg : 7 d : Gastrointestir : tachycardia, o rhoea, Vomiti	decreased activity, decrease in appetite, Diar-
Speci NOAE Expos		: Rat : 500 mg/kg : 28 d	
	EL EL sure time et Organs	: Dog : 6 mg/kg : 17 mg/kg : 28 d : Gastrointestir : decreased ad appetite	nal tract tivity, Gastrointestinal tract damage, decrease in
Not c	ration toxicity lassified based on ava		
-	rience with human e <u>ponents:</u>	xposure	
Moln	upiravir: ral Information		eadache, Gastrointestinal disturbance e most common side effects are: ack pain
12. ECOL	OGICAL INFORMATI	ON	
	oxicity ponents:		
<b>Cellu</b> Toxic	<b>lose:</b> ity to fish	Exposure tim	s latipes (Japanese medaka)): > 100 mg/l e: 48 h sed on data from similar materials
	<b>upiravir:</b> ity to algae/aquatic	: EC10 ( Raphi mg/l End point: Gr Exposure tim	

according to the Globally Harmonized System



# Molnupiravir Capsule Formulation

Version 8.0	Revision Date: 28.09.2024		99210-00014	Date of last issue: 06.07.2024 Date of first issue: 24.08.2020
			Method: OECD Te	est Guideline 201
Toxic	ity to microorganisms	:	EC10: 143.1 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition of activated sludge
Toxic icity)	ity to fish (Chronic tox-	:	EC10: 5.8 mg/l Exposure time: 32 Species: Pimepha Method: OECD Te	ales promelas (fathead minnow)
aquat	Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)		Exposure time: 21 Species: Daphnia Method: OECD Te	magna (Water flea)
Ecot	oxicology Assessment			
Acute	e aquatic toxicity	:	This product has r	no known ecotoxicological effects.
Chroi	nic aquatic toxicity	:	This product has r	no known ecotoxicological effects.
Persi	istence and degradabili	ty		
Com	ponents:			
Cellu	llose:			
Biode	egradability	:	Result: Readily bio	odegradable.
Moln	upiravir:			
Biode	egradability	:	Result: Readily bid Biodegradation: 8 Exposure time: 28 Method: OECD Te	31 % 3 d
Bioa	ccumulative potential			
Com	ponents:			
Moln	upiravir:			
Partit	ion coefficient: n- nol/water	:	log Pow: -0.534 pH: 7	
Mobi	lity in soil			
Com	ponents:			
Moln	upiravir:			
Distri	bution among environ- al compartments	:	OECD Test Guide log Koc: 1.45	eline 106

according to the Globally Harmonized System



## Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	28.09.2024	6199210-00014	Date of first issue: 24.08.2020

#### Other adverse effects

No data available

#### 13. DISPOSAL CONSIDERATIONS

Disposal methods	
Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	<ul> <li>Empty containers should be taken to an approved waste han- dling site for recycling or disposal.</li> <li>If not otherwise specified: Dispose of as unused product.</li> </ul>

#### 14. TRANSPORT INFORMATION

#### **International Regulations**

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

## Transport in bulk according to IMO instruments

Not applicable for product as supplied.

#### Special precautions for user

Not applicable

## **15. REGULATORY INFORMATION**

#### Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

#### **16. OTHER INFORMATION**

Revision Date	:	28.09.2024
Further information		
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

according to the Globally Harmonized System



## Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	28.09.2024	6199210-00014	Date of first issue: 24.08.2020

Date format :		dd.mm.yyyy			
Full text of other abbreviations					
ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)			
ACGIH / TWA	:	8-hour, time-weighted average			

AIIC - Australian Inventory of Industrial Chemicals: ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN